HIGHLIGHTS
- who: Enrico Maffini from the Agostino Gemelli University Polyclinic (IRCCS), Italy have published the article: The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia, in the Journal: (JOURNAL)
- what: Study design, gilteritinib is the only FLT3-ITD with a label indication after transplant in Europe.
SUMMARY
Genomic loss of mismatched HLA haplotype, HLA downregulation, inhibition of allogeneic T_cells response through overexpression of inhibitory receptors, perturbation of anti and pro-inflammatory cytokines productions are the best-known alterations at the molecular TABLE 1 Tumor Mechanisms of Immune . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.